James Hamrick, MD, senior medical director, Flatiron Health, discusses how clinical trials can be improved in the community setting during the ACCC 44th Annual Meeting & Cancer Center Business Summit.
James Hamrick, MD, senior medical director, Flatiron Health, discusses how clinical trials can be improved in the community setting during the ACCC 44th Annual Meeting & Cancer Center Business Summit.
New APL Treatment Shows Promise: Higher Survival Rates, Less Toxicity
July 6th 2024ATO/ATRA plus idarubicin showed superior 2-year EFS (88% vs 70%) and 5-year EFS (87% vs 55%) compared to ATRA/chemotherapy. The trial indicated lower hematologic toxicity with ATO/ATRA, including reduced rates of thrombocytopenia and neutropenia.
Read More